Search Results

Nucleix announced that the results from the company’s North American pivotal clinical study evaluating the performance of Bladder EpiCheck® as a non-invasive and objective novel methylation-based PCR urine test for the surveillance of non-muscle invasive bladder cancer (NMIBC) recurrence were presented in a podium presentation at the American Urological Association (AUA) Annual Meeting 2024 in San Antonio, Texas.

Nucleix Demonstrates Potential of its PCR EpiCheck ® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes.

Nucleix Receives Reimbursement for Bladder EpiCheck ® in the Netherlands.

Nucleix today announced recent updates in its lung cancer detection program for early-stage disease.

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck ® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting.

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced participation in the Association Francaise d’Urologie (AFU) Registry of the Therapeutic Management and Follow-Up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU).

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced the appointment of commercial veteran, Michael G. Vicari, as Chief Commercial Officer.

Nucleix has received 510 clearance from the U.S. Food and Drug Administration to market Bladder EpiCheck® for use as a non-invasive method for surveillance of tumor recurrence in patients previously diagnosed with non-muscle invasive bladder cancer, in conjunction with cystoscopy.

Nucleix will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck® Lung Atlas, at the American Association for Cancer Research (AACR) Annual Event in Orlando, April 14-19.